25219 - Ph3 precemtabart tocentecan +/- bevacizumab vs trifluridine/tipiracil + bevacizumab in CRC

A randomized, open-label, 3-arm Phase 3 study of precemtabart tocentecan with or without bevacizumab compared to trifluridine/tipiracil plus bevacizumab in participants with previously treated metastatic colorectal cancer (PROCEADE-CRC-03)

Disease Types: Colorectal

Available at: Arlington Heights, Chicago, Niles